Certified Advisory Corp Has $1.89 Million Stake in Pfizer Inc. (NYSE:PFE)

Certified Advisory Corp decreased its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 12.0% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 71,158 shares of the biopharmaceutical company's stock after selling 9,693 shares during the period. Certified Advisory Corp's holdings in Pfizer were worth $1,888,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Bradley Foster & Sargent Inc. CT raised its position in shares of Pfizer by 3.2% during the second quarter. Bradley Foster & Sargent Inc. CT now owns 271,120 shares of the biopharmaceutical company's stock worth $7,586,000 after acquiring an additional 8,375 shares during the last quarter. Mercer Global Advisors Inc. ADV increased its position in Pfizer by 0.6% in the second quarter. Mercer Global Advisors Inc. ADV now owns 897,017 shares of the biopharmaceutical company's stock worth $25,099,000 after purchasing an additional 5,246 shares during the period. Meiji Yasuda Asset Management Co Ltd. raised its holdings in Pfizer by 1.4% during the 2nd quarter. Meiji Yasuda Asset Management Co Ltd. now owns 190,811 shares of the biopharmaceutical company's stock worth $5,339,000 after purchasing an additional 2,572 shares during the last quarter. Blair William & Co. IL lifted its position in Pfizer by 85.9% during the 2nd quarter. Blair William & Co. IL now owns 1,953,310 shares of the biopharmaceutical company's stock valued at $54,654,000 after purchasing an additional 902,376 shares during the period. Finally, Sienna Gestion boosted its stake in shares of Pfizer by 0.8% in the 2nd quarter. Sienna Gestion now owns 221,295 shares of the biopharmaceutical company's stock valued at $6,189,000 after purchasing an additional 1,771 shares during the last quarter. Institutional investors own 68.36% of the company's stock.

Insider Activity

In related news, Director Scott Gottlieb acquired 1,000 shares of the firm's stock in a transaction dated Wednesday, October 30th. The stock was bought at an average price of $28.24 per share, for a total transaction of $28,240.00. Following the acquisition, the director now directly owns 10,000 shares of the company's stock, valued at approximately $282,400. The trade was a 11.11 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 0.06% of the stock is owned by corporate insiders.

Pfizer Stock Down 0.7 %

Shares of NYSE:PFE traded down $0.19 during midday trading on Friday, reaching $26.30. 35,146,711 shares of the company were exchanged, compared to its average volume of 33,531,398. The firm has a market cap of $149.06 billion, a PE ratio of 35.55, a P/E/G ratio of 0.64 and a beta of 0.64. Pfizer Inc. has a fifty-two week low of $24.48 and a fifty-two week high of $31.54. The stock has a fifty day simple moving average of $26.09 and a two-hundred day simple moving average of $28.00. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.64 by $0.42. The firm had revenue of $17.70 billion for the quarter, compared to the consensus estimate of $14.92 billion. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The company's revenue for the quarter was up 31.2% on a year-over-year basis. During the same quarter last year, the business posted ($0.17) EPS. As a group, sell-side analysts forecast that Pfizer Inc. will post 2.94 earnings per share for the current year.

Pfizer Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, January 24th will be paid a dividend of $0.43 per share. This is a boost from Pfizer's previous quarterly dividend of $0.42. This represents a $1.72 annualized dividend and a dividend yield of 6.54%. The ex-dividend date of this dividend is Friday, January 24th. Pfizer's dividend payout ratio (DPR) is currently 227.03%.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on the stock. Cantor Fitzgerald restated an "overweight" rating and issued a $45.00 price objective on shares of Pfizer in a report on Wednesday, October 23rd. Guggenheim cut their price target on Pfizer from $35.00 to $33.00 and set a "buy" rating on the stock in a research note on Wednesday, December 11th. Citigroup began coverage on Pfizer in a research note on Friday, October 25th. They set a "neutral" rating and a $30.00 price objective for the company. Truist Financial cut their target price on Pfizer from $36.00 to $32.00 and set a "buy" rating on the stock in a research note on Wednesday, December 18th. Finally, UBS Group decreased their target price on Pfizer from $31.00 to $29.00 and set a "neutral" rating for the company in a research report on Wednesday, January 8th. One research analyst has rated the stock with a sell rating, eight have given a hold rating, six have issued a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $32.00.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.